We are happy to sign this agreement with AMR, who are focused on the Japanese market. Having a distribution partner with expertise in this geography is a great opportunity for Polymer Factory to exploit this market further. We look forward to entering 2025 with this agreement in place.

Regardless of order size, we are delighted to support our customer with highly sophisticated dendritic nanomaterials tailored for RNA applications within the life science field. This is not our first collaboration, and I remain cautiously optimistic about additional opportunities arising from this partnership

A strong patent protection is valuable both for Polymer Factory and for potential future partners. Our main commercial focus is on Europe and the USA, why this decision from the USPTO is an important step forward in our journey to commercialize the DNG platform.

Calibration in the high molecular weight range is very important to be able to accurately analyze larger molecules; both biomolecules, such as proteins or intact antibodies, to enable better or earlier diagnostics for viral or bacterial infections, and synthetic polymers for advanced synthetic material research. There are currently no high-performing synthetic calibrants commercially offered for these mass ranges, and Polymer Factory is aiming to take a good position in this growing market.

I would like to thank everyone who participated in the rights issue – both existing shareholders for their continued confidence in our business, and new shareholder whom I welcome to Polymer Factory. Despite a though market climate we have secured sufficient funding to support our acceleration of sales and ongoing build-up and maintenance of Polymer Factory’s portfolio of IP rights and ISOs. Following the certification of our quality management system (ISO 13485) and the launch of our business area DNGs, we are confident that the funds from the rights issue create a solid ground for broadening our customer base further, as well as increase sales. I look forward to continuing the work to fulfill our financial and operational objectives together with the rest of the team.

We are very happy to receive this grant from the European Defence Fund, and to be part of such an exciting project. This will really provide Polymer Factory an opportunity to widen the applications for our dendritic technologies; with the aim to create products that help protect EU citizens against CBRN threats, this project can have a true impact on the future.

Nano-SHIELD aims at delivering tomorrow’s groundbreaking respiratory device products to counteract threats such as chemical, biological, radiological, and nuclear. Polymer Factory’s dendritic products will be one of the key components in the development of nanofiber-based filtration membranes. Our dendritic products will empower the membranes with function being both scavengers and neutralizer of harmful bacteria, viruses etc.

To successfully receive this certification is a milestone for Polymer Factory, and something we have been greatly focusing on during 2022. Having a certified quality management system has been a goal for the company as it further underlines the level of quality in our work and shows that we are committed to always providing our customers with best-in-class services. We are very proud to fulfill this objective for 2022.

We are excited to launch the first generation of DNGs as a new product line of nanocarriers. Our DNGs are unique in the sense of being available as stable and ready-to-formulate products suited to encapsulate and deliver drugs, peptides, biologics and much more. This will allow our customers to straightforwardly screen the performance of their desired active compounds without a large investment in formulation optimization. With this in mind, it’s my belief that the DNG platform can be a contender to the limited number of available delivery platforms such as Lipidic Nanoparticles (LNPs) and Liposomes.

We consider the external targets particularly important, and they are a subset of our internal targets and action plans. Today's economic environment accelerates the need to secure our ability to finance investments in future growth drivers with revenues from our commercial products and from our partnerships based on our development projects and the product offer. I look forward to updating the shareholders on our progress with these new objectives.

The signed agreement is a logical and important first step that defines the relationship between both parties and with respect to current and future delivered products covered by the MTA. Personally, I am quite excited over this relationship and as a company we will ensure to deliver high-quality customized precision nanocarriers for the internal evaluation by our customer. Polymer Factory will monitor the progress and support our customer with all means necessary to increase the success rate of our delivered products.

Our dendritic nanomaterial platform has unlimited potential in the life science sector, ranging from therapeutic to diagnostic applications. The fact is, since becoming a public Company, we have secured customized orders of significant size from two global life science companies. This foretells the demand and interest for our dendritic products among life science companies and underlines the quality and unique position of our Company. The Company’s goal is to help our customers succeed by leveraging the benefits of dendritic amplification, and we are always working to bring these collaborations into long-term relationships.

Our dendritic nanomaterial platform has unlimited potential in the life science sector, ranging from therapeutic to diagnostic applications. The fact is, since becoming a public Company, we have secured customized orders of significant size from two global life science companies. This foretells the demand and interest for our dendritic products among life science companies and underlines the quality and unique position of our Company. The Company’s goal is to help our customers succeed by leveraging the benefits of dendritic amplification, and we are always working to bring these collaborations into long-term relationships.

With this agreement secured, renowned researchers from UMass will now have the opportunity to explore Polymer Factory’s dendrimer nanocarrier platform as the most sophisticated dendritic probes on the market, with emphasis on identifying novel design of therapies for patients with troublesome diseases including cancer, diabetes and other immunocompromised conditions.

We are very happy to announce that all key personnel wanted to participate fully in the warrants program. All of our employees are committed to making Polymer Factory a success, and we will continue to work hard to reach our goals. The aim of the incentive program was to engage the employees to be even more involved in the company’s journey, and to also share the success they are working hard to achieve.

We are happy to engage Biohub as a distributor to increase our exposure to the Chinese market, being the second largest economy in the world. Polymer Factory continuously evaluate new sales channels and distribution opportunities to open new markets that can support the Company’s growth. The Chines market is very attractive, and we are excited to work together with Biohub to make this a growing market for Polymer Factory.

The underlying market is growing rapidly and according to the company, their products have advantages compared to competitors. Furthermore, the growth strategy has great potential, and the high insider ownership sends very positive signals.

Our dendritic nanomaterial platform has unlimited potential in the life science sector, ranging from therapeutic to diagnostic applications. The fact is, since becoming a public Company, we have secured customized orders of significant size from two global life science companies. This foretells the demand and interest for our dendritic products among life science companies and underlines the quality and unique position of our Company. The Company’s goal is to help our customers succeed by leveraging the benefits of dendritic amplification, and we are always working to bring these collaborations into long-term relationships.

BowtieD® dendrimers are the pinnacle of polymer-based carriers for therapeutic, diagnostic applications and much more. The foundation of this class of dendrimers is resonated by their extraordinary features such as flawless structures, biodegradability, and multitude of two active sites that are bundled in a bow-tied configuration. Never before has such dendritic technology been commercially available and with this launch, I truly believe that Polymer Factory will move its position, globally, by providing customers with next generation carriers to address challenges in high-demanding life-science technologies.

We are excited for the launch of a new and groundbreaking platform of dendritic materials, and with this trademark secured, Polymer Factory will be first-in-the-world and only commercial provider of next generation precision dendrimers - BowtieD®. As a nanotechnology company, our mission is to position our dendritic products for future technological breakthroughs suited for the life science sector, and the commercialization of the BowtieD® dendrimers is a major and exciting step for Polymer Factory. We envisage a successful and strong launch of this product platform that will unlock current pain-points for our customers.

Our SpheriCal® platform is very innovative and adds value to users around the world. As with all Polymer Factory products, we have a truly international customer base, which is why it is important for us to strengthen our positions in the markets. One step in doing this is the registration of strong trademarks. Earlier this year, we signed an OEM agreement for one product in the platform, and we hope that this extension will aid in securing further agreements in the future.

We are happy to announce this agreement with Bruker who is a global leader in the mass spectrometry industry. The application of our SpheriCal® products in Bruker’s MALDI Biotyper-based antibiotic susceptability testing portfolio is just one example of the diversity and applicability of our cutting-edge calibrant platform. We look forward to a fruitful and long-lasting relationship with Bruker.

Latest expansion of research capabilities of the market leading MALDI Biotyper® (MBT) systems (with the MBT sirius as the current innovation) towards fast antimicrobial susceptibility testing (AST) requires the implementation of new MALDI-TOF standards and calibrants. The high quality calibrants in Polymer Factory’s Spherical products are a very good fit for Bruker’s upcoming AST solutions. Especially regarding performance, precision, safety, and future regulations MALDI-TOF based AST testing will be based on assay standardization, which put innovative solutions for calibrants and standards in a central position of assay development. Hence, the Spherical products can play an important role in our assay development process.

We are happy to announce this agreement with Bruker who is a global leader in the mass spectrometry industry. The application of our SpheriCal® products in Bruker’s MALDI Biotyper-based antibiotic susceptability testing portfolio is just one example of the diversity and applicability of our cutting-edge calibrant platform. We look forward to a fruitful and long-lasting relationship with Bruker.

Latest expansion of research capabilities of the market leading MALDI Biotyper® (MBT) systems (with the MBT sirius as the current innovation) towards fast antimicrobial susceptibility testing (AST) requires the implementation of new MALDI-TOF standards and calibrants. The high quality calibrants in Polymer Factory’s Spherical products are a very good fit for Bruker’s upcoming AST solutions. Especially regarding performance, precision, safety, and future regulations MALDI-TOF based AST testing will be based on assay standardization, which put innovative solutions for calibrants and standards in a central position of assay development. Hence, the Spherical products can play an important role in our assay development process.

We are happy for this substantial single order related to our hyperbranched products. This product segment has great commercial usability, especially for coating applications. This is due to their larger scale availability coupled with unique branched structures that enhances the processibility and final performance of the coatings.